Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies

ConclusionsDSP-7888 Dosing Emulsion was well tolerated, with no dose-limiting toxicities, in patients with recurrent or advanced malignancies. Higher WT1-specific CTL induction activity was noted with ID compared with SC administration; because of this, the ID route was selected for further evaluation in the clinical program.Trial registrationClinicalTrials.gov identifier: NCT02498665.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research